PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)
Holstein, Sarah A., Mian, Hira, Touzeau, Cyrille, Kingsley, Edwin, Vogl, Dan, Zuniga, Richard, Suryanarayan, Kaveri, Wang, Shining, Thesillat‐Versmee, Laura, Liu, Yuyin, Chen, Tian, Zhang, Yefei, Parot, Xavier, Lee, Hans C.
Published in HemaSphere (08.08.2023)
Published in HemaSphere (08.08.2023)
Get full text
Journal Article
357 TAK-573, an anti-CD38–attenuated interferon alpha (IFNα) fusion protein (Attenukine™), has demonstrated IFNα receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma
Collins, Sabrina, Joshi, Adarsh, Shen, Lei, Das, Subhasree, Suryanarayan, Kaveri, Bottino, Dean, Li, Cheryl, Curley, Michael, Wang, Dannie, Abadier, Michael, Larson, Ryan, Parot, Xavier
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
Well-differentiated grade 3 digestive neuroendocrine tumors: Myth or reality? The PRONET study group
Scoazec, Jean-Yves, Couvelard, Anne, Monges, Genevieve, Leteurtre, Emmanuelle, Belleannee, Genevieve, Guyetant, Serge, Duvillard, Pierre, Danjoux, Marie, Parot, Xavier, Lepage, Come
Published in Journal of clinical oncology (20.05.2012)
Published in Journal of clinical oncology (20.05.2012)
Get full text
Journal Article
Final Results from the First-in-Human Phase 1/2 Study of Modakafusp Alfa, an Immune-Targeting Attenuated Cytokine, in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
Vogl, Dan T., Atrash, Shebli, Holstein, Sarah A., Nadeem, Omar, Benson, Don M., Suryanarayan, Kaveri, Liu, Yuyin, Collins, Sabrina, Parot, Xavier, Kaufman, Jonathan L.
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
Dose escalation of a phase 1b/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (pts) with metastatic solid tumors
Johnson, Melissa Lynne, Abdul-Karim, Raghad, Sommerhalder, David, Hafez, Navid, Wang, Shining, Li, Cheryl, Liu, Yuyin, Yang, Lili, Collins, Sabrina, Parot, Xavier, Strauss, James F.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article
Modakafusp Alfa (TAK-573), an Immunocytokine, Shows Clinical Activity in Patients with Relapsed/Refractory Multiple Myeloma; Updated Results from a First-in-Human Phase 1 Study
Vogl, Dan T., Kaufman, Jonathan L., Holstein, Sarah A., Atrash, Shebli, Nadeem, Omar, Janakiram, Murali, Suryanarayan, Kaveri, Liu, Yuyin, Collins, Sabrina, Parot, Xavier, Chaudhry, Maria
Published in Blood (23.11.2021)
Published in Blood (23.11.2021)
Get full text
Journal Article
TAK-573, an Anti-CD38/Attenuated Ifnα Fusion Protein, Has Clinical Activity and Modulates the Ifnα Receptor (IFNAR) Pathway in Patients with Relapsed/Refractory Multiple Myeloma
Vogl, Dan T., Kaufman, Jonathan L., Holstein, Sara A., Nadeem, Omar, O'Donnell, Elizabeth, Suryanarayan, Kaveri, Collins, Sabrina, Parot, Xavier, Chaudhry, Maria
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article
Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)
Scoazec, Jean-Yves, Couvelard, Anne, Monges, Geneviève, Guyétant, Serge, Bisot-Locard, Segolène, Parot, Xavier, Lepage, Côme
Published in Neuroendocrinology (01.01.2017)
Published in Neuroendocrinology (01.01.2017)
Get more information
Journal Article
P-011: A randomized phase 2 study of modakafusp alfa (TAK-573) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) with a pilot diversity, equity, and inclusion (DEI) strategy
Kaufman, Jonathan, Atrash, Shebli, Benson, Don, Holstein, Sarah, Nadeem, Omar, Biran, Noa, Suryanarayan, Kaveri, Liu, Yuyin, Robinson, LaShell, Correa, Karen, Enwemadu, Victoria, Parot, Xavier, Vogl, Dan
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Published in Clinical lymphoma, myeloma and leukemia (01.08.2022)
Get full text
Journal Article
P-203 Rationale and design of three ongoing phase 1/2 trials of modakafusp alfa, an innate immunity enhancer, in patients with multiple myeloma: The innovate clinical development program
Mian, Hira, Touzeau, Cyrille, Holstein, Sarah, Kingsley, Edwin, Vogl, Dan, Zuniga, Richard, Kim, Kihyun, Suryanarayan, Kaveri, Wang, Shining, Thesillat-Versmee, Laura, Liu, Yuyin, Chen, Tian, Zhang, Yefei, Parot, Xavier, Lee, Hans
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
CD38-BINDING FUSION PROTEIN COMBINATION THERAPY
GUPTA, Neeraj, WILSON, David, LABOTKA, Richard, PAROT, Xavier, WANG, Shining, COLLINS, Sabrina, SAMPSON, Jim, THESILLAT-VERSMEE, Laura, SURYANARAYAN, Kaveri, POGUE, Sarah, LI, Shuang
Year of Publication 13.06.2024
Get full text
Year of Publication 13.06.2024
Patent
CD38-BINDING FUSION PROTEIN COMBINATION THERAPY
GUPTA, Neeraj, LABOTKA, Richard, PAROT, Xavier, WANG, Shining, COLLINS, Sabrina, SAMPSON, Jim, THESILLAT-VERSMEE, Laura, SURYANARAYAN, Kaveri, LI, Shuang
Year of Publication 23.05.2024
Get full text
Year of Publication 23.05.2024
Patent
CD38-BINDING FUSION PROTEIN COMBINATION THERAPY
GUPTA, Neeraj, WILSON, David, LABOTKA, Richard, PAROT, Xavier, WANG, Shining, COLLINS, Sabrina, SAMPSON, Jim, THESILLAT-VERSMEE, Laura, SURYANARAYAN, Kaveri, POGUE, Sarah, LI, Shuang
Year of Publication 04.04.2024
Get full text
Year of Publication 04.04.2024
Patent
CD38-BINDING FUSION PROTEIN COMBINATION THERAPY
GUPTA, Neeraj, LABOTKA, Richard, PAROT, Xavier, WANG, Shining, COLLINS, Sabrina, SAMPSON, Jim, THESILLAT-VERSMEE, Laura, SURYANARAYAN, Kaveri, LI, Shuang
Year of Publication 04.04.2024
Get full text
Year of Publication 04.04.2024
Patent
DOSING OF CD38-BINDING FUSION PROTEIN
GUPTA, Neeraj, YANG, Hui, PAROT, Xavier, GARCIA RIBAS, Ignacio, WANG, Shining, COLLINS, Sabrina, CHEN, Tian, LARSON, Ryan, SURYANARAYAN, Kaveri, LIU, Yuyin, LI, Shuang
Year of Publication 30.11.2023
Get full text
Year of Publication 30.11.2023
Patent
CD38-binding fusion protein combination therapy
COLLINS, SABRINA, WANG, SHINING, THESILLAT-VERSMEE, LAURA, GUPTA, NEERAJ, SAMPSON, JIM, POGUE, SARAH, LABOTKA, RICHARD, SURYANARAYAN, KAVERI, LI, SHUANG WU, WILSON, DAVID, PAROT, XAVIER
Year of Publication 16.06.2024
Get full text
Year of Publication 16.06.2024
Patent
DOSIFICACIÓN DE LA PROTEÍNA DE FUSIÓN DE CD38
COLLINS, SABRINA, WANG, SHINING, LI, SHUANG WU CHERYL, YANG, HUI, GUPTA, NEERAJ, CHEN, TIAN, LARSON, RYAN, LIU, YUYIN, SURYANARAYAN, KAVERI, GARCIA RIBAS, IGNACIO, PAROT, XAVIER
Year of Publication 28.08.2024
Get full text
Year of Publication 28.08.2024
Patent
Dosing of CD38-binding fusion protein
COLLINS, SABRINA, WANG, SHINING, LI, SHUANG WU (CHERYL), RIBAS, IGNACIO GARCIA, YANG, HUI, GUPTA, NEERAJ, CHEN, TIAN, LARSON, RYAN, SURYANARAYAN, KAVERI, LIU, YU-YIN, PAROT, XAVIER
Year of Publication 16.03.2024
Get full text
Year of Publication 16.03.2024
Patent